Zhong Yuan Bio-Technology Holdings Limited (ZHYBF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Zhong Yuan Bio-Technology Holdings Limited (ZHYBF) trades at $2.02 with AI Score 64/100 (Grade B+). Zhong Yuan Bio-Technology Holdings Limited develops and markets nervonic acid-based health supplements in China. Market cap: $35.75M, Sector: Consumer defensive.
Last analyzed: Mar 18, 2026Analyst Coverage for ZHYBF: ZHYBF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates ZHYBF against Consumer Defensive peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
ZHYBF: 2/4 perspectives are bullish. Dominant signal: Izzy Englander bullish.
Zhong Yuan Bio-Technology Holdings Limited (ZHYBF) Consumer Business Overview
Zhong Yuan Bio-Technology Holdings Limited focuses on developing and marketing nervonic acid-based health supplements in China, distinguishing itself with products like Neuro Enhancer oils and Life's NA candies, targeting a niche market within the consumer defensive sector with a focus on cognitive health.
What Is the Investment Thesis for ZHYBF?
Zhong Yuan Bio-Technology Holdings Limited presents a focused investment opportunity within the Chinese health supplement market, specifically targeting cognitive health through nervonic acid-based products. The company's high gross margin of 90.9% indicates strong pricing power and efficient production. However, a high P/E ratio of 118.63 suggests the stock may be overvalued, and the company's small market capitalization of $0.04 billion and high beta of 4.70 indicate high volatility and risk. Growth catalysts include expanding distribution channels and increasing brand awareness in the Chinese market. The company's profitability, indicated by a 13.3% profit margin, is a positive sign, but investors should carefully consider the risks associated with investing in a small-cap OTC-listed company.
Based on FMP financials and quantitative analysis
ZHYBF Key Highlights
- Market capitalization of $0.04 billion indicates a small-cap company with potential for high growth but also higher risk.
- P/E ratio of 118.63 suggests the stock may be overvalued compared to its earnings.
- Gross margin of 90.9% demonstrates strong pricing power and efficient cost management.
- Profit margin of 13.3% indicates profitability in the health supplement market.
- Beta of 4.70 signifies high volatility compared to the overall market.
Who Are ZHYBF's Competitors?
ZHYBF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| BRCNF Burcon NutraScience Corporation | $1.61 | -0.86% | $20.43M | 59 |
| CELV Cellev8 Nutrition Inc. | $0.08 | +0.00% | $10.72M | 52 |
| CFOO China Foods Holdings Ltd. | $0.66 | +0.00% | $13.45M | 44 |
| DTEAF DAVIDsTEA Inc. | $0.71 | +2.01% | $21.67M | 41 |
| GPAGF Gruma, S.A.B. de C.V. | $18.10 | +0.00% | $6.18B | 66 |
| PNGAF Pangea Wellness Inc. | $0.36 | +5.92% | $5.45M | 65 |
| FSRCY First Resources Limited | $184.15 | +0.00% | $2.85B | 64 |
| FTROF First Resources Limited | $2.26 | +0.00% | $3.50B | 64 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ZHYBF's Key Strengths?
- Focus on nervonic acid-based health supplements.
- High gross margin of 90.9%.
- Established brand (Muzhiyuan-Neuro Enhancer) in China.
- Proprietary formulations.
What Are ZHYBF's Weaknesses?
- Small market capitalization ($0.04 billion).
- High P/E ratio (118.63).
- Limited geographic reach within China.
- High beta (4.70) indicating high volatility.
What Could Drive ZHYBF Stock Higher?
- Potential expansion of distribution channels in China.
- Launch of new nervonic acid-based health supplements.
- Increasing health awareness among Chinese consumers.
- Growing demand for cognitive health products.
- Strategic partnerships with research institutions.
What Are the Key Risks for ZHYBF?
- Intense competition from larger health supplement companies.
- Regulatory changes in the Chinese health supplement industry.
- Economic slowdown in China affecting consumer spending.
- Limited financial disclosure due to OTC listing.
- High price volatility and illiquidity of the stock.
What Are the Growth Opportunities for ZHYBF?
- Expanding Distribution Channels: Zhong Yuan Bio-Technology can grow by expanding its distribution channels beyond online platforms to include more retail partnerships and direct sales. The Chinese health supplement market is vast, and increased accessibility will drive sales. The company could target partnerships with major pharmacy chains and health food stores across China. This expansion could potentially double sales within the next three years, capturing a larger share of the growing health supplement market.
- Increasing Brand Awareness: A significant growth opportunity lies in increasing brand awareness through targeted marketing campaigns. The company can leverage social media platforms, influencer marketing, and online advertising to reach a wider audience. Focusing on the unique benefits of nervonic acid and its impact on cognitive health can differentiate the brand. A successful marketing campaign could increase brand recognition by 50% within two years, leading to higher sales and market share.
- Product Diversification: Zhong Yuan Bio-Technology can diversify its product line by introducing new health supplements based on nervonic acid and other beneficial ingredients. This could include products targeting different age groups and health conditions. Expanding the product portfolio will attract a broader customer base and reduce reliance on a single product line. Introducing 2-3 new products within the next 18 months could increase revenue by 30%, diversifying the company's income streams.
- Geographic Expansion within China: While currently focused on specific regions, Zhong Yuan Bio-Technology can expand its geographic reach within China. Targeting Tier 2 and Tier 3 cities, where there is growing demand for health supplements, can unlock new markets. This expansion requires establishing distribution networks and marketing efforts tailored to these regions. Expanding into 5-10 new cities within the next two years could increase sales by 25%, tapping into previously underserved markets.
- Strategic Partnerships: Forming strategic partnerships with research institutions and healthcare providers can enhance the credibility and market acceptance of Zhong Yuan Bio-Technology's products. Collaborating on research studies to validate the benefits of nervonic acid and partnering with healthcare professionals to recommend the products can build trust with consumers. These partnerships can lead to increased sales and brand recognition, potentially increasing revenue by 20% within the next three years.
What Opportunities Does ZHYBF Have?
- Expanding distribution channels.
- Increasing brand awareness through marketing.
- Product diversification.
- Geographic expansion within China.
What Threats Does ZHYBF Face?
- Competition from larger health supplement companies.
- Changing consumer preferences.
- Regulatory changes in the health supplement industry.
- Economic slowdown in China.
What Are ZHYBF's Competitive Advantages?
- Proprietary formulations of nervonic acid-based supplements.
- Brand recognition in the Chinese market under the Muzhiyuan-Neuro Enhancer brand.
- Focus on a niche market segment (cognitive health).
- Established distribution channels in China.
What Does ZHYBF Do?
Zhong Yuan Bio-Technology Holdings Limited, based in Wanchai, Hong Kong, specializes in the development and marketing of health supplements centered around nervonic acid. The company's origins lie in recognizing the potential health benefits of nervonic acid, particularly its role in brain health and nerve function. Their flagship product, Neuro Enhancer nervonic acid oils, aims to improve cognitive function and overall well-being. The product portfolio also includes Muzhiyuan acer truncatum formula oils, Life's NA candies, and Acer Truncatum seedlings. Additionally, Zhong Yuan Bio-Technology offers a demyelination diagnostic kit and nervonic acid supplements. These products are marketed under the Muzhiyuan-Neuro Enhancer brand, targeting health-conscious consumers in China. The company distributes its products through various channels, including online platforms and retail partnerships. Zhong Yuan Bio-Technology Holdings Limited operates within the consumer defensive sector, specifically the packaged foods industry, catering to the growing demand for health and wellness products in China. The company's focus on nervonic acid positions it uniquely in the market, although it faces competition from other health supplement providers.
What Products and Services Does ZHYBF Offer?
- Develops nervonic acid-based health supplements.
- Markets health supplements in China.
- Offers Neuro Enhancer nervonic acid oils.
- Provides Muzhiyuan acer truncatum formula oils.
- Sells Life's NA candies.
- Offers seedlings of Acer Truncatum.
- Provides demyelination diagnostic kits.
- Sells nervonic acid supplements.
How Does ZHYBF Make Money?
- Develops and manufactures nervonic acid-based health supplements.
- Markets and sells products directly to consumers through online platforms.
- Partners with retailers and distributors to expand market reach.
- Generates revenue through product sales.
What Industry Does ZHYBF Operate In?
Zhong Yuan Bio-Technology Holdings Limited operates within the consumer defensive sector, specifically in the packaged foods and health supplements industry. The Chinese health supplement market is experiencing significant growth, driven by increasing health awareness and disposable incomes. The competitive landscape includes both domestic and international players offering a wide range of health products. Zhong Yuan Bio-Technology differentiates itself through its focus on nervonic acid-based supplements, targeting cognitive health. The company's success depends on its ability to effectively market its products and establish a strong brand presence in the competitive Chinese market.
Who Are ZHYBF's Key Customers?
- Health-conscious consumers in China.
- Individuals seeking cognitive health benefits.
- Customers interested in natural health supplements.
- Consumers looking for products under the Muzhiyuan-Neuro Enhancer brand.
ZHYBF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2024
ZHYBF Latest News
No recent news available for ZHYBF.
ZHYBF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ZHYBF.
Price Targets
Wall Street price target analysis for ZHYBF.
ZHYBF MoonshotScore
What does this score mean?
The MoonshotScore rates ZHYBF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Ting Ting Chang
CEO
Ting Ting Chang serves as the CEO of Zhong Yuan Bio-Technology Holdings Limited, managing a team of 23 employees. Details regarding Chang's prior experience and educational background are not available in the provided data. However, as CEO, Chang is responsible for the strategic direction and overall performance of the company, focusing on the development and marketing of nervonic acid-based health supplements in the Chinese market. Her leadership is crucial for navigating the competitive landscape and driving growth.
Track Record: Due to limited information, it is difficult to assess Ting Ting Chang's track record. However, under her leadership, Zhong Yuan Bio-Technology Holdings Limited has maintained a high gross margin of 90.9% and a profit margin of 13.3%. The company's focus on nervonic acid-based supplements and its established brand (Muzhiyuan-Neuro Enhancer) in China suggest a strategic direction aimed at capturing a niche market within the health supplement industry. Further information is needed to fully evaluate her accomplishments.
ZHYBF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, encompassing securities that are not eligible for quotation on OTCQX or OTCQB. Companies in this tier often have limited or no financial disclosure, and may not meet minimum financial standards. Investing in OTC Other securities carries significant risks due to the lack of regulatory oversight and transparency compared to exchanges like the NYSE or NASDAQ. These companies may be defunct, shell companies, or in bankruptcy.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited or no financial disclosure.
- Potential for fraud or manipulation.
- High price volatility.
- Illiquidity and difficulty in trading shares.
- Lack of regulatory oversight.
- Verify the company's legal status and registration.
- Obtain and review any available financial statements.
- Assess the company's management team and their experience.
- Understand the company's business model and competitive landscape.
- Evaluate the company's regulatory compliance.
- Assess the liquidity and trading volume of the stock.
- Consult with a financial advisor before investing.
- Company has a registered address in Hong Kong.
- Company has a website and product listings.
- Company has been in operation for several years.
- Company has a recognizable brand name (Muzhiyuan-Neuro Enhancer).
What Investors Ask About Zhong Yuan Bio-Technology Holdings Limited (ZHYBF) — Consumer Defensive
What does Zhong Yuan Bio-Technology Holdings Limited do?
Zhong Yuan Bio-Technology Holdings Limited focuses on the development, marketing, and sale of nervonic acid-based health supplements in China. Their core product line includes Neuro Enhancer nervonic acid oils, Muzhiyuan acer truncatum formula oils, Life's NA candies, and Acer Truncatum seedlings. The company targets health-conscious consumers seeking cognitive health benefits and overall well-being. They operate primarily in the Chinese market, leveraging the growing demand for health supplements and natural remedies.
What are the main risks for ZHYBF?
ZHYBF faces several risks, including intense competition from larger health supplement companies, regulatory changes in the Chinese health supplement industry, and potential economic slowdown in China. As an OTC-listed company, it also faces risks related to limited financial disclosure, high price volatility, and illiquidity. The company's reliance on a niche market segment (cognitive health) makes it vulnerable to changing consumer preferences and the emergence of alternative health solutions. Investors should carefully assess these risks before investing.
How does Zhong Yuan Bio-Technology Holdings Limited manage supply chain and input cost risks?
Information on Zhong Yuan Bio-Technology Holdings Limited's specific supply chain management and input cost risk mitigation strategies is not available. However, as a health supplement company, it likely faces risks related to the sourcing of raw materials, particularly nervonic acid and Acer Truncatum. The company's high gross margin of 90.9% suggests it has some pricing power and efficient cost management practices. Further research is needed to fully understand its supply chain resilience and ability to manage input cost fluctuations.
What is Zhong Yuan Bio-Technology Holdings Limited's geographic revenue mix?
Zhong Yuan Bio-Technology Holdings Limited primarily operates in the Chinese market. Specific details regarding its geographic revenue mix are not available. However, it can be inferred that the majority of its revenue is generated within China, given its focus on the Chinese health supplement market and its brand presence in the region. Expansion into new geographic regions within China represents a potential growth opportunity for the company.
What are the key factors to evaluate for ZHYBF?
Zhong Yuan Bio-Technology Holdings Limited (ZHYBF) holds an AI score of 64/100 (moderate). Not financial advice.
How frequently does ZHYBF data refresh on this page?
ZHYBF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven ZHYBF's recent stock price performance?
Zhong Yuan Bio-Technology Holdings Limited (ZHYBF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Focus on nervonic acid-based health supplements. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ZHYBF overvalued or undervalued right now?
Valuing Zhong Yuan Bio-Technology Holdings Limited (ZHYBF) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available on OTC-listed companies.
- Analyst ratings and price targets may not be available.
- Financial data may be limited or unaudited.